Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Date:12/9/2008

e development of most cancers, the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft-tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis. High pAkt is often seen in tumors that are resistant to conventional cancer treatments, including radiotherapy, chemotherapy, endocrine therapy, and especially therapy with some of the newer biologicals.

To date, over 1,700 patients have been treated with KRX-0401 in trials conducted both in the United States and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not appear to cause myelosuppression (depression of the immune system that may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of perifosine are nausea, vomiting, diarrhea and fatigue, but these are either mild or non-existent in lower doses that have induced tumor regression. Responses have been seen with both daily and weekly regimens. At the doses studied, the daily regimens were better tolerated.

In Phase 1/2 trials, KRX-0401 has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. KRX-0401 has shown single agent partial responses in renal
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
6. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
10. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
11. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or ... products, announced today that the Company will present at the ... 2013 at the Le Parker Meridian hotel, 119 W. 56 ... . The presentation is scheduled to begin at 2:15 p.m. ... Heska Heska Corporation (NASDAQ: HSKA - ...
(Date:5/22/2013)... , May 22, 2013 /PRNewswire-iReach/ -- World markets ... with the latest trends and events, companies now ... predict where an industry is headed next, so ... (Photo: http://photos.prnewswire.com/prnh/20130522/CG19099 ) ... market research publisher GlobalData, offer decision makers and ...
(Date:5/22/2013)... Calif. , May 22, 2013   Accuray ... that its management is scheduled to present at the ... York on Thursday, June 6, 2013 at ... webcast of the presentation will be available online from ... http://www.accuray.com/investors . The webcast replay of the ...
Breaking Medicine Technology:Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 2Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 3Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 4
... TOKYO, May 22, 2007 /PRNewswire-FirstCall/ -- Sosei ... the,successful completion of a study of its ... for the treatment of cancer,breakthrough pain. , ... centre, open-label,single dose, cross-over, randomised study of ...
... /PRNewswire/ -- A three-year,follow-up subset analysis presented today ... that the CYPHER(R),Sirolimus-eluting Coronary Stent had results comparable ... and better outcomes,than bare metal stents (BMS) in ... arteries. , The CYPHER(R) Stent results in the ...
Cached Medicine Technology:Sosei Announces Successful Completion of AD 923 Pharmacokinetic,Study in the USA 2Sosei Announces Successful Completion of AD 923 Pharmacokinetic,Study in the USA 3Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 2Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 3Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 4
(Date:5/23/2013)... (PRWEB) May 23, 2013 On May 23, ... research and advocacy, commends Salem High School senior Max Merget ... cancer. , According to a Patch.com article, Max ... with anaplastic ependymoma -- a large malignant tumor in the ... He underwent surgery but the tumor came back a year ...
(Date:5/23/2013)... To help members more easily ... pleased to announce integration of its advanced ... new upgrade automatically transfers real-time step data onto ... their company’s team standings, view progress on rewards, ... , Walkingspree also offers an integrated nutritional module ...
(Date:5/23/2013)... South Carolina (PRWEB) May 23, 2013 ... anniversary being in practice. For 25 years, Jeff ... honest legal advice with a focus on personal ... years having worked for insurance companies, he offers clients ... how insurance companies operate, which enables him better serve ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Canadian ... its Max! Healthy Vending Machines, and that's in sync ... report prepared for the Canada Organic Trade Association (COTA). ... organic food and beverages each year. This makes the ... the world. , As a Canadian leader in ...
(Date:5/23/2013)... Portland, Oregon (PRWEB) May 23, 2013 Better ... touches as it prepares to launch its one of ... Final training of management staff will be completed May 29th, ... Chris and Heather Richardson completed on site training in Portland ... the 29th to complete operational training. , "It really is ...
Breaking Medicine News(10 mins):Health News:Voices Against Brain Cancer Commends Young Man for Raising Money for Brain Cancer Despite Fighting His Own Battle 2Health News:Walkingspree Expands Device Options with Fitbit to Increase Member Engagement in Corporate Wellness Programs 2Health News:Walkingspree Expands Device Options with Fitbit to Increase Member Engagement in Corporate Wellness Programs 3Health News:Ezell Law Firm Celebrates 25 Years in Practice 2Health News:Max! Healthy Vending Machines in Tune with Burgeoning Organic Foods Market 2Health News:Better Life Maids of Portland Oregon Prepares For a Summer of 2013 Launch 2
... Alexandria, VA - The 2011 Annual Meeting & OTO ... and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ... convene September 11-14, 2011 in San Francisco, CA. ... and several hundred instruction course hours for attendees, the ...
... effective in helping patients manage their Type 2 diabetes using ... of Maryland School of Medicine researchers. The study is being ... Care . The study, one of the first to scientifically ... blood sugar control the amount of hemoglobin A1c in ...
... Reporter , FRIDAY, July 29 (HealthDay News) -- The ... it uses to approve and regulate "moderate-risk" medical devices ... a highly anticipated federal report released Friday. Instead, ... process that ensures the devices go through more rigorous ...
... College of Radiology and society of Breast Imaging, two top ... issued a statement on a controversial study published in the ... which claimed that there is no evidence that mammography served ... countries where screening has been implemented. , , The ACR ...
... -- The brains of two of four former Canadian ... associated with concussions, say researchers with the Canadian Sports ... (of the Toronto Argonauts and Hamilton Tiger-Cats) and Jay ... encephalopathy (CTE). Both players suffered repeated concussions during their ...
... July 29 (HealthDay News) -- Excluding children from discussions about ... a new study finds. Parents and medical professionals need ... them in decisions, said the researchers from Dublin, Ireland. ... to 18, at three hospitals and found that the kids ...
Cached Medicine News:Health News:World's largest meeting of ear, nose and throat doctors 2Health News:UM School of Medicine finds that mobile phone technology helps patients manage diabetes 2Health News:Report Urges New Review System for Medical Devices 2Health News:Report Urges New Review System for Medical Devices 3Health News:Concussion Project Finds Disease in Two Autopsied Brains 2Health News:Study Finds Kids Want More Info About Their Hospital Care 2
... Codman Sofwire Cable System, ... fixation including sublaminar interspinous ... facial surgery, sternotomy closure. ... and a complete set ...
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%....
... Inductive demineralized bone matrix ... and cancellous chips will be ... bone matrix particle size is ... chip particle size is 1 ...
Demineralized Freeze-dried Bone Allograft (DFDBA) processed from cortical bone. Demineralized cortical powder is free of all soft tissue....
Medicine Products: